Danish giant says fierce competition and high launch costs will eat into earnings next year
The Wall Street Journal
By ANNA MOLIN
Oct. 29, 2015 9:04 a.m. ET
Denmark’s Novo Nordisk A/S posted a 29% jump in third-quarter net profit, but warned that fierce pricing competition and the high launch costs of a diabetes treatment recently approved in the U.S. would more than halve the pace of earnings growth next year.
Third-quarter net profit rose to 8.38 billion Danish kroner ($1.24 billion) on net sales of 26.8 billion kroner, up 20% on the year.
Novo Nordisk, the world’s largest...
To Read the Full Story, Subscribe or Sign In
POPULAR on WSJ